Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Pieter Sonneveld*, Meletios A. Dimopoulos, Mario Boccadoro, the PERSEUS Trial Investigators, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. Van De Donk, Eirini KatodritouFredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. Van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. De Boer, Robin Carson, Paula Rodriguez-Otero, Joan Bladé, Philippe Moreau

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

33 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology